2018 Rectal Tumor Board (Occurs Weekly, Every Tuesday)

Date & Location
Occurs weekly every Tuesday starting on 1/2/2018 at 8:00 AM, FHCI, Room 182, Orlando, Orlando, FL

Target Audience
Colon and Rectal, Family Medicine, Fellow / Resident, Gastroenterology, Hematology/Oncology, Internal Medicine, Oncology, Pathology, Radiation Oncology, Radiology, Student, Surgery (All)

Multidisciplinary Team of Physicians discuss the latest staging, NCCN / Rectal Tumor Board Guidelines and study materials as applicable for each patient presented. The Physicians are fully engaged in finding the best treatment available for favorable outcomes.


At the end of this course, participants should be able to:
  1. Utilize a multidisciplinary, case-based approach to discuss recent treatment guidelines to improve care for various cancer patients.
  2. Evaluate current clinical trials underway so that appropriate cancer patients may be considered for enrollment in those trials.
  3. Share lessons learned in treatment of difficult cases in order to provide alternative therapies and/or develop new protocols for management of cancer patients.
  4. Review site specific NCCN/Rectal Guidelines as appropriate per case.


COST: Complimentary

Occurs Every Tuesday of each Month - 8:00 AM - 9:00 AM


Florida Hospital is accredited by the Florida Medical Association (FMA) to provide continuing medical education for physicians.   Florida Hospital designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™.

Physicians should only claim the credit commensurate with the extent of their participation in the activity.


Florida Hospital Cancer Institute
Conference Room, Suite 182
2501 N. Orange Ave., Orlando, FL 32804


Florida Hospital's CPD Committee members have no financial relationships with any proprietary entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients.

The following speakers have financial relationships with the companies listed:

  • Dr. Matthew Albert - Stryker
  • Dr. Juan Pablo Arnoletti - Pfizer, Inc.
  • Dr. Jeremy Robert Burt - Hälsa Labs LLC, Yellow Dot Innovations LLC, Innovative Air LLC, Abbott Laboratories.
  • Dr. Raul Castillo - GlaxoSmithKline, Merck and Company, Inc., ABBvi, and Pfizer, Inc.
  • Dr. Sebastian De La Fuente - Johnson and Johnson, and TransEnterix.
  • Dr. Teresa H.debeche-Adams - Applied Medical, and Trans Enterix.
  • Dr. John Monson - Johnson and Johnson, and Medtronic, Inc.
  • Dr. George Nassif Jr. - Applied Medical, and Mallincrodkt.
  • Dr. Ravi Shridhar - Biocompatilbes.
  • Dr. Mark Soliman - Intutive Surgical.

    The following speakers have no financial relationships with any proprietary entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients:

    • Dr. Osama 'Sam' Atallah
    • Dr. Matthew Biagioli
    • Dr. Christopher Brady
    • Dr. Jeremy Marcus Drake
    • Dr. Na'im K. Fanaian
    • Dr. Nicholas Feranec
    • Dr. Antonio Gonzalez
    • Dr. Mark Harvey
    • Dr. Justin Kelly
    • Dr. Bruce Orkin
    • Dr. Jie Ouyang
    • Dr. Yaman Suleiman
    • Dr. Tien-Anh Tran
    • Dr. Ahmed Zakari


      Participants must text the lecture code to receive the evaluation; the evaluation must be completed to receive both the certificate and credit with CE Broker.